Published in Lancet on January 10, 2005
Overcoming Endocrine Resistance in Metastatic Breast Cancer (OVER) | NCT02394496
Effect of Aromatase Inhibitors on Bones and Genes | NCT00603967
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat (2010) 3.35
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol (2012) 3.03
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat (2012) 3.02
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol (2009) 2.14
CYP2D6 testing in breast cancer: ready for prime time? Oncology (Williston Park) (2009) 2.11
Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer (2007) 2.07
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. J Acupunct Meridian Stud (2015) 2.02
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res (2008) 2.01
Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer (2010) 1.93
Surgical mammography reporting in a limited resource environment. World J Surg (2010) 1.93
Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ (2005) 1.89
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids (2006) 1.89
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer (2009) 1.84
Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res (2006) 1.68
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol (2006) 1.68
Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57
Persistent mobility disability after neurotoxic chemotherapy. Phys Ther (2010) 1.55
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol (2016) 1.52
Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst (2009) 1.47
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst (2008) 1.45
Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat (2010) 1.42
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther (2007) 1.42
Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring) (2009) 1.41
Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue. PLoS One (2017) 1.40
Breast cancer in young women and its impact on reproductive function. Hum Reprod Update (2009) 1.40
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther (2007) 1.39
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat (2009) 1.37
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol (2008) 1.36
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol (2006) 1.30
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res (2010) 1.30
Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf (2013) 1.28
Update on estrogens and the skeleton. J Clin Endocrinol Metab (2010) 1.25
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res (2011) 1.23
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res (2007) 1.22
Tissue microarrays in clinical oncology. Semin Radiat Oncol (2008) 1.21
The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics (2009) 1.19
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract (2007) 1.17
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids (2007) 1.17
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat (2010) 1.17
Skeletal complications of breast cancer therapies. Clin Cancer Res (2006) 1.16
Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat (2009) 1.15
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer (2010) 1.13
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors. Integr Cancer Ther (2009) 1.13
Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol (2010) 1.13
Caring for survivors of breast cancer: perspective of the primary care physician. Curr Oncol (2011) 1.11
Drug-induced hematologic syndromes. Adv Hematol (2009) 1.11
Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer (2007) 1.10
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat (2009) 1.09
Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol (2010) 1.08
Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res (2014) 1.07
Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res (2007) 1.06
Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer (2006) 1.06
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther (2009) 1.06
Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat (2007) 1.06
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. J Clin Oncol (2015) 1.05
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int (2012) 1.05
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance? Br J Cancer (2011) 1.05
Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res (2008) 1.05
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res (2012) 1.03
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol (2013) 1.02
Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol (2010) 1.02
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med (2013) 1.01
Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics (2010) 1.01
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol (2008) 1.00
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat (2008) 1.00
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int (2007) 0.99
Exercise for the management of side effects and quality of life among cancer survivors. Curr Sports Med Rep (2009) 0.99
Reduction in mortality from breast cancer. BMJ (2005) 0.99
Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat (2012) 0.99
Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist (2011) 0.99
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A (2010) 0.99
Management of cancer treatment-induced bone loss. Nat Rev Rheumatol (2013) 0.99
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int (2010) 0.99
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res (2005) 0.98
Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat (2011) 0.98
The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. J Steroid Biochem Mol Biol (2012) 0.98
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res (2011) 0.97
Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer (2012) 0.96
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer (2013) 0.96
Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol (2009) 0.96
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer (2009) 0.96
A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer (2010) 0.96
A Wilcoxon-type test for trend. Stat Med (1985) 13.22
Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ (1990) 10.93
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet (1993) 7.46
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet (2005) 7.25
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Quality and the use of time in general practice: widening the discussion. BMJ (1989) 5.59
Variations in breast cancer management between a teaching and a non-teaching district. Eur J Cancer (1992) 5.54
Effects of breast conservation on psychological morbidity associated with diagnosis and treatment of early breast cancer. Br Med J (Clin Res Ed) (1986) 5.37
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer (1996) 5.24
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med (1992) 5.18
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet (2002) 5.04
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Informed consent in medical research. BMJ (1998) 4.57
Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. Lancet (1986) 4.55
Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet (1976) 4.53
Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol (1994) 4.50
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol (2000) 4.03
Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet (1987) 3.84
A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79
Ethics of clinical research: lessons for the future. BMJ (1989) 3.77
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology (1986) 3.70
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Psychological effects of being offered choice of surgery for breast cancer. BMJ (1994) 3.48
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet (1994) 3.38
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
Mild cervical dyskaryosis: safety of cytological surveillance. Lancet (1992) 3.09
Do we need informed consent? Lancet (1986) 3.02
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. J Bone Joint Surg Am (2006) 2.71
Can magnetic-resonance imaging help elucidate natural history of breast cancer multicentricity? Lancet (1998) 2.70
Breast cancer, desmoid tumours, and familial adenomatous polyposis--a unifying hypothesis. Lancet (1993) 2.69
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol (1992) 2.67
Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res (1985) 2.62
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Primary management of carcinoma of the breast. Lancet (1993) 2.59
Screening for breast cancer, time to think--and stop? Lancet (1995) 2.58
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58
Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol (2012) 2.45
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42
The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. Br J Cancer (1982) 2.39
Structural organization and functional analysis of centromeric DNA in the fission yeast Schizosaccharomyces pombe. Mol Cell Biol (1988) 2.37
Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep (1987) 2.37
Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg (1984) 2.36
Financial ties as part of informed consent to postmarketing research. Attitudes of American doctors and patients. BMJ (1995) 2.36
Clinical syndromes of mastalgia. Lancet (1976) 2.35
Effect of smoking cessation on cervical lesion size. Lancet (1996) 2.35
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol (2008) 2.34
The cyclotron saga continues. BMJ (1989) 2.34
Mass screening for cancer of the breast. Lancet (1968) 2.33
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer (1996) 2.30
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J (Clin Res Ed) (1984) 2.19
Is clinical breast examination an acceptable alternative to mammographic screening? BMJ (2000) 2.18
Oestrogen as a reticuloendothelial stimulant in patients with cancer. Br Med J (1971) 2.14
Can results from clinical trials be generalized? Nat Med (1995) 2.13
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol (2007) 2.05
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Time to abandon TNM staging of breast cancer? Lancet (1992) 2.05
The second specialty of general physicians. J R Coll Physicians Lond (1981) 2.04
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest (1980) 2.03
The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore) (1979) 1.99
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer (2001) 1.96
Accelerated decline in cervical cancer mortality in England and Wales. Lancet (1995) 1.95
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Psychosexual trauma of an abnormal cervical smear. Br J Obstet Gynaecol (1988) 1.90
Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol (2004) 1.90
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer (2003) 1.90
Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients. J Infect Dis (1996) 1.85
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol (2006) 1.85